Compare Moderna, Inc. (MRNA) vs D Wave Quantum Inc (QBTS) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

D-Wave Quantum (QBTS) trades at $20.75, up 2.77% today, but faces bearish technical signals amid mixed earnings performance. The company reported a Q2 2026 loss of $0.10 per share, missing estimates, while revenue remained flat at $3.1 million. Despite negative profitability metrics, analyst consensus remains unanimously bullish with a $38.29 price target, reflecting optimism about quantum computing adoption and strong bookings growth.

The stock presents high-risk speculative potential with significant valuation concerns trading at 584x sales. While institutional interest and government funding support long-term quantum computing prospects, persistent losses and declining revenue create substantial execution risk. Investors must weigh Wall Street optimism against fundamental weaknesses in this emerging technology play.